Table 4. Association between serum IGF-1 level and 3-month functional outcome.
| Serum IGF-1 | OR [95% CI] | p |
|---|---|---|
| Model 1 | 0.177 | |
| Q1 | Reference | |
| Q2 | 1.23 [0.69-2.17] | 0.481 |
| Q3 | 1.23 [0.69-2.19] | 0.486 |
| Q4 | 1.95 [1.07-3.57] | 0.029 |
| Model 2 | 0.424 | |
| Q1 | Reference | |
| Q2 | 0.90 [0.49-1.65] | 0.722 |
| Q3 | 0.59 [0.30-1.14] | 0.115 |
| Q4 | 0.81 [0.40-1.63] | 0.547 |
| Model 3 | 0.172 | |
| Q1 | Reference | |
| Q2 | 0.71 [0.34, 1.51] | 0.762 |
| Q3 | 0.35 [0.15, 0.80] | 0.773 |
| Q4 | 0.62 [0.27, 1.43] | 0.172 |
Model 1: crude OR; model 2: model 1 adjusted for age and sex; model 3: model 2 adjusted for prestroke modified Rankin Scale score, body mass index, Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, diabetes mellitus, previous stroke, smoking, initial National Institutes of Health Stroke Scale score, white blood cell count, initial glucose level, and high-sensitivity C-reactive protein.
CI: confidence interval, IGF-1: insulin-like growth factor-1, OR: odds ratio.